Affymetrix (AFFX) says Q3 revenue will be about $80M, short of consensus $85M, due to concerns...
Affymetrix (AFFX) says Q3 revenue will be about $80M, short of consensus $85M, due to concerns about tighter academic funding globally and euro weakness. Some $18M will come from its eBioscience business, without which revenues will be "flat to slightly down" for the year. Results are due after the close Oct. 31.
From other sites
at CNBC.com (Nov 13, 2014)
at CNBC.com (Dec 2, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs